Stemsynergy Therapeutics Inc.

Miami, FL

UEI
WVEMHJFUNJ97
CAGE
59DT1
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
1951 NW 7th Ave #300, Miami, FL 33136, USA

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
Development of novel WNT inhibitors to treat colorectal cancers R43CA310499 National Cancer Institute (NIH) $399,998
Small molecule MYC degraders as novel cancer therapeutic agents R44CA268456 National Cancer Institute (NIH) $2,939,827
Small molecule n-MYC degraders as novel cancer therapeutic agents R43CA268456 National Cancer Institute (NIH) $799,998
Development of NOTCH1-selective small molecule inhibitor for the treatment of cancer R44CA261490 National Cancer Institute (NIH) $4,898,781
Small molecule inhibitors of notch activation complex kinase (nack) as novel cancer therapeutic agents R43CA246945 National Cancer Institute (NIH) $399,999

Latest 5 listed here. See the rest on GovTribe.

Similar vendors

Vendor Location Primary NAICS
Senex Biotechnology Inc. UEI G8XKMW3DYMQ6 Maynard, MA 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Recombination Therapeutics LLC UEI JLYJMA2WFYE3 Philadelphia, PA 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Quercus Molecular Design, LLC UEI ZHH5N3KV48A5 Avon, CT 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Atux Iskay Group LLC UEI C7JPQ5F3UUH7 Plainsboro Township, NJ 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Seak Therapeutics, LLC UEI HBTSD5J8NL84 Memphis, TN —

See more similar vendors on GovTribe

About the company

Written by GovTribe AI ·

Stemsynergy Therapeutics Inc. is a for-profit biotechnology company that provides drug discovery and development services focused on novel cancer therapeutics. Through federal grant awards from the National Institutes of Health National Cancer Institute, Stemsynergy discovers and develops small molecule drug candidates that target various oncogenic proteins implicated across multiple cancer types.

Stemsynergy Therapeutics has received over $6 million in federal grants to support preclinical development of its pipeline of targeted anti-cancer therapies. As a prime recipient, Stemsynergy has conducted research and development activities spanning hit discovery, lead optimization, investigational new drug-enabling studies, and early efficacy testing for small molecule inhibitors of N-Myc, C-Myc, Notch1, and other oncogenic drivers of tumor progression. Specific grant-funded projects have focused on improving potency, selectivity, pharmacokinetic properties, and preliminary safety and efficacy of Stemsynergy's lead N-Myc protein degrader, Notch1 transcription complex inhibitor, and related compounds in cancer models. The company aims to advance its most promising drug candidates toward clinical trials through continued federal funding opportunities.

Quick answers

Is Stemsynergy Therapeutics Inc. registered in SAM.gov?

Yes. Stemsynergy Therapeutics Inc.'s SAM.gov registration is active through June 29, 2027.

What is Stemsynergy Therapeutics Inc.'s most recent federal award?

Stemsynergy Therapeutics Inc.'s most recent federal grant award is Development of novel WNT inhibitors to treat colorectal cancers (R43CA310499), from National Cancer Institute (NIH), on September 3, 2026.

On GovTribe

See Stemsynergy Therapeutics Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login